Ovarian Axis Hormones and Adrenal Androgens and Measurements of Satiation, Postprandial Satiety, and Hunger in Pre- and Post-menopausal Women

Overview

About this study

The purpose of this study is to determine the correlation between ovarian axis hormones and adrenal androgens and changes in satiation, postprandial satiety, and hunger in pre- and post-menopausal women. Since differential hormone profile is considered an important underlying physiologic change through the menopausal transition, changes in ovarian sexual hormones and adrenal androgen levels may have an association with changes in satiation, postprandial satiety, and hunger.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Premenopausal group

  • Age 40-48 at the time of original study recruitment.
  • Regular menstrual periods for at least 1 year on no hormonal contraception at the time of their participation in the original study.

Postmenopausal group

  • Age 52-60 at the time of original study recruitment.
  • Confirmed menopausal status at the time of their participation in the original study: no menstrual periods for at least 1 year (but no more than 2 years).

Exclusion Criteria:

  • History of hysterectomy.
  • History of surgical, chemical, or radiation-induced menopause (i.e., oophorectomy, aromatase inhibitors, chemotherapy for cancer treatment, or radiation therapy).
  • Use of any drug that can affect estrogen production or signaling (e.g., GnRH agonists and antagonists, estrogen receptor modulators, etc.).
  • Use of systemic estrogen and/or progesterone (oral contraceptives, contraceptive implants, hormone replacement therapy).
  • Use of non-hormonal contraceptive methods that can affect the regularity of menstrual cycles (e.g., intrauterine devices).
  • History of hypothalamic or pituitary disease (e.g., pituitary adenomas, empty sella, pituitary surgery, hypothalamic masses).
  • Patients who denied future use of biological samples or further contact from the previous listed IRBs.

Eligibility last updated 4/18/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Maria Hurtado Andrade, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions